Evolva and LEHVOSS UK Ltd. have signed an agreement for the distribution of Evolvas Veri-teTM Resveratrol in over a dozen European countries for use in dietary supplements through LEHVOSS subsidiaries and expert teams across Europe. Sales from the agreement are expected to amount to around CHF 1.5 million by the end of 2025. Over a dozen European countries are covered under the agreement.

It is anticipated that the agreement will generate approximately CHF 1.5 million in sales by the conclusion of 2025. The agreement is further testimony to Evolvas market expansion activities. Following market launch and successful entry into five South-East Asian countries as well as Brazil with Veri-teTM Resveratrol for use in foods and dietary supplements over the recent past, the agreement with LEHVOSS now also paves the way to strengthen distribution in important European countries.

Veri-teTM Resveratrol is the main pillar of Evolvas Health Ingredients (HI) business and was a key driver for the 14% revenue growth in HI recorded in the first half of 2023.